Lighting Up Cancer: New Tech Aims to End Repeat Breast Surgeries

WALTHAM, MA – April 16, 2026 – For the one in eight women who will develop breast cancer, a lumpectomy can represent a beacon of hope—a chance to remove the tumor while conserving the breast. But this hope is often shadowed by a persistent fear: the post-surgery phone call delivering the news that the margins weren't clear, and a second operation is needed. This scenario is a reality for up to 30% of patients undergoing breast-conserving surgery, a statistic that carries a heavy emotional and physical toll.

A Massachusetts-based life sciences company is aiming to change that narrative with a novel technology designed to give surgeons a real-time, illuminated view of any cancer left behind. Lumicell, Inc. is bringing its FDA-approved LumiSystem to a national audience this week, with a feature on the television series Health Uncensored with Dr. Drew set to air on April 19th. The segment will spotlight how fluorescence-guided imaging is arming surgeons with unprecedented information directly in the operating room.

A New Light in the Operating Room

The technology, called the LumiSystem, is a two-part, drug-device combination that received a dual, high-bar approval from the U.S. Food and Drug Administration in April 2024. The approval followed the agency's most stringent review pathways for both a new drug and a medical device, a significant regulatory milestone.

The process begins a few hours before surgery, when a patient receives an intravenous injection of LUMISIGHT (pegulicianine). This proprietary optical imaging agent is designed to seek out cancer. The agent remains inactive until it encounters specific enzymes—cathepsins and matrix metalloproteases—which are found in higher concentrations in and around tumor cells. When LUMISIGHT interacts with these enzymes, it activates and becomes fluorescent.

After the surgeon removes the primary tumor specimen through a standard lumpectomy, the second part of the system comes into play. The surgeon uses the Lumicell Direct Visualization System (DVS), a handheld probe connected to a touchscreen monitor, to scan the walls of the lumpectomy cavity. The probe emits a light that causes the activated LUMISIGHT in any remaining cancerous tissue to glow. This provides an immediate, real-time map of residual disease that is invisible to the naked eye, allowing the surgeon to identify and remove it on the spot.

This approach directly targets the primary challenge in lumpectomy surgery: ensuring no malignant cells are left behind. The goal is to achieve “negative” or “clear” margins, meaning a border of healthy tissue surrounds the removed tumor. When pathology reports later find cancer cells at the edge of the specimen, it results in a “positive” margin and often necessitates a repeat surgery, known as a re-excision.

The Clinical Challenge and the Promise of Precision

The pivotal Phase 3 INSITE trial, which supported the FDA's approval, provided a clear look at the system's potential. The study enrolled 406 patients across 14 U.S. sites and was designed to assess the technology's ability to identify residual cancer in the lumpectomy cavity after the standard-of-care procedure was complete.

The results were striking. The LumiSystem detected remaining cancer in 7.6% of patients. Critically, in the majority of these cases, the residual cancer was found in margins that had been deemed negative by standard pathology, meaning it would have been missed without the aid of the fluorescence imaging. Overall, the system demonstrated an 84% diagnostic accuracy in detecting residual cancer in real-time.

While the technology's specificity—its ability to correctly identify tissue as non-cancerous—was high at over 85%, its sensitivity—the ability to detect all cancerous tissue—was approximately 49%. This indicates that while the system may not find every single remaining cancer cell, it is highly reliable when it shows a clear cavity and successfully identifies cancer that other methods miss. For 14.5% of patients in the trial who had positive margins after their initial lumpectomy, the use of the LumiSystem to guide the removal of additional tissue resulted in a conversion to final negative margins, potentially sparing those patients a second surgery.

"Breast cancer surgeons are making critical decisions in real time, often without the ability to see all remaining disease," said Dr. Jorge Ferrer, Chief Scientific Officer at Lumicell, in the company's announcement. "Participating in Health Uncensored with Dr. Drew provided an opportunity to discuss why enhanced visualization during surgery matters and how this technology, providing information never before available, may help address a longstanding clinical challenge."

Beyond the Scalpel: The Patient Experience

While the clinical data is compelling, the technology's most profound impact may be on the patient's journey. The waiting period between a lumpectomy and the final pathology report is fraught with anxiety. The possibility of a re-operation brings not only the physical burden of another surgery and recovery but also a significant psychological weight, prolonging the uncertainty and emotional distress of a cancer diagnosis.

The upcoming television segment will feature Dr. Fedra Fallahian, a breast surgical oncologist, alongside a patient named Kristie Cole, who underwent a procedure using the LumiSystem. By including a direct patient perspective, the discussion aims to highlight the human side of this innovation—the value of potentially getting a more definitive result from the very first surgery.

Patient advocacy groups have long emphasized that reducing re-operation rates is a critical goal for improving quality of life. Innovations that provide greater peace of mind and allow patients to move forward with their recovery and subsequent treatments, such as radiation, more quickly are seen as invaluable. The ability to reduce the number of surgeries is a tangible benefit that resonates deeply with patients and their families.

From Lab to Living Room: Adoption and Access

Featuring the LumiSystem on a mainstream platform like Health Uncensored with Dr. Drew marks a strategic effort to educate the public and the broader medical community. However, the journey from FDA approval to widespread adoption involves clearing several hurdles.

Hospitals must weigh the upfront capital investment in the DVS device against the potential long-term savings from reduced re-operations. Securing reimbursement codes from Medicare and private insurers is another critical step to ensure the technology is accessible. Surgeons and operating room staff also require training to integrate the system seamlessly into their workflow.

Furthermore, the technology comes with important safety considerations. LUMISIGHT carries an FDA Boxed Warning for the risk of serious hypersensitivity reactions, including anaphylaxis, which occurred in a small fraction of patients (0.6%) in clinical trials. Medical teams must be prepared for this possibility. Additionally, the system can be affected by blue dyes commonly used for sentinel lymph node mapping, requiring careful procedural planning.

Despite these challenges, the introduction of real-time fluorescence imaging into the breast cancer operating room represents a significant step forward. It is part of a broader movement in medicine toward more precise, data-driven surgical interventions. As this technology moves from clinical trials into broader practice, its ultimate impact will be measured not just in reduced re-operation rates, but in the number of patients who can leave the operating room with greater confidence that their cancer is truly gone.